Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. St Vincent Hosp And Hlth Care
WARNING LETTER
•St Vincent Hosp And Hlth Care•August 26, 2013

St Vincent Hosp And Hlth Care – FDA Warning Letter, Aug 26, 2013

Record Details

The FDA issued a Warning Letter to St. Vincent Health following an inspection of the St. Vincent Hospital and Health Care Center Institutional Review Board (SVHHCC IRB) conducted from August 12-26, 2013. The inspection, part of the Bioresearch Monitoring Program, aimed to ensure compliance with 21 CFR parts 50 and 56 for human subject protection. The FDA concluded the IRB did not adhere to applicable statutory requirements and regulations.

Two significant violations were identified. First, the IRB failed to determine at the time of initial review that clinical investigations involving children complied with 21 CFR part 50, subpart D (Additional Safeguards for Children in Clinical Investigations) [21 CFR 56.109(h)]. This was observed in 31 active pediatric studies, and the IRB's corrective action response was deemed inadequate for the majority. Second, the IRB failed to fulfill membership requirements [21 CFR 56.107] by allowing nonmembers to vote on clinical investigations, as evidenced in multiple meeting minutes.

The FDA acknowledged the IRB's corrective actions for membership issues, including SOP updates and training, appear adequate if properly implemented. However, the IRB must provide written assurance and documentation of completed subpart D reviews for all remaining pediatric studies. The letter requires a written response within fifteen business days detailing corrective actions, documentation, and projected completion dates. Failure to adequately address these violations may result in further regulatory action, emphasizing the critical need for full compliance to protect human subjects.

Company
St Vincent Hosp And Hlth Care
Inspection date
August 26, 2013
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Thomas N. Moreno
  • Kyle DeFur
  • Tina G. Noonan
View Company Profile

ID · 09b8d8f7-dd29-4d2a-a94a-00cfebbb421c

Violation Codes9
21 CFR 5021 CFR 5621 CFR 56.109(h)21 CFR 50.5021 CFR 50.5121 CFR 50.5221 CFR 50.5321 CFR 56.11521 CFR 56.107

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore St Vincent Hosp And Hlth Care
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.